IL17A and colorectal carcinoma: Studies have also shown the benefits of a combination of anti-PD-1 with anti-IL-17 therapy in microsatellite stable (MSS) CRC (67), and blocking IL-17 signaling may significantly enhance the response to anti-PD1 treatment both in vitro and in vivo (68).